• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CONMED Corporation

    4/7/26 8:50:38 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    DEFA14A 1 ef2006877_defa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549



     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     


    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐


    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    CONMED CORPORATION

    (Name of Registrant as Specified In Its Charter)

    Payment of Filing Fee (Check the appropriate box):

     

    ☑

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





    Your Vote Counts!  CONMED CORPORATION  ATTN: CORPORATE SECRETARY, LEGAL DEPARTMENT 11311 CONCEPT BLVD  LARGO, FL 33773  You invested in CONMED CORPORATION and it’s time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the  availability of proxy materials for the stockholder meeting to be held on May 18, 2026.  Get informed before you vote  View the Proxy Statement, the Notice of Annual Meeting and the 2025 Annual Report online OR you can receive a free paper  or email copy of the material(s) by requesting prior to May 4, 2026. If you would like to request a copy of the material(s) for the Annual Meeting and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote Virtually at the Meeting*  May 18, 2026  11:30 AM EDT  Virtually at: www.virtualshareholdermeeting.com/CNMD2026  CONMED CORPORATION  2026 Annual Meeting  Vote by May 17, 2026 11:59 PM ET. For shares held in a Plan, vote by May 13, 2026 11:59 PM ET.  *Please check the meeting materials for any special requirements for meeting attendance.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V85688-P42296


     Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. Election of seven directors to serve on the Company’s Board of Directors.  For All  Nominees:  Patrick J. Beyer 05) Mark Kaye  David Bronson 06) Kim Kelderman  LaVerne H. Council 07) Barbara J. Schwarzentraub  Charles M. Farkas  2. Advisory vote to approve named executive officer compensation.  For  3. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.  For  NOTE: Such other business as may properly come before the meeting and any adjournment or postponement thereof.  Voting Items  Board Recommends  V85689-P42296 


    Get the next $CNMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    3/17/2026$39.00Overweight → Neutral
    Piper Sandler
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    More analyst ratings

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

    4/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024. Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2

    1/28/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Chief Financial Officer Transition

    Todd Garner to step down as CONMED's CFO, effective March 15, 2026, and remain In an Advisory Role Through November 2, 2026 Company Initiates Comprehensive Search for Next Chief Financial Officer CONMED Reaffirms Full-Year 2025 Revenue and Adjusted EPS Outlook CONMED Corporation (NYSE:CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. "On beh

    1/8/26 4:55:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    SEC Filings

    View All

    SEC Form DEFA14A filed by CONMED Corporation

    DEFA14A - CONMED Corp (0000816956) (Filer)

    4/7/26 8:50:38 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by CONMED Corporation

    DEF 14A - CONMED Corp (0000816956) (Filer)

    4/7/26 8:23:14 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CONMED Corporation

    SCHEDULE 13G/A - CONMED Corp (0000816956) (Subject)

    3/26/26 5:41:52 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Beyer Pat

    4 - CONMED Corp (0000816956) (Issuer)

    4/2/26 4:05:51 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Lalomia Brent

    4/A - CONMED Corp (0000816956) (Issuer)

    3/18/26 2:07:58 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Schabacker Matthew

    4/A - CONMED Corp (0000816956) (Issuer)

    3/18/26 2:04:27 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/14/24 3:37:54 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/10/24 5:29:04 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/8/24 4:20:48 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CONMED downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded CONMED from Overweight to Neutral and set a new price target of $39.00

    3/17/26 7:55:41 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Needham

    Needham downgraded CONMED from Buy to Hold

    6/12/25 7:52:09 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Stifel with a new price target

    Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

    4/28/25 8:32:52 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Financials

    Live finance-specific insights

    View All

    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

    4/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024. Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2

    1/28/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a me

    1/5/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/13/24 4:22:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/12/24 12:53:28 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    2/13/24 5:02:29 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    View All

    CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

    5/21/25 7:03:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    2/9/21 4:01:00 PM ET
    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology